Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich to Buy JRH Biosciences for $370M

NEW YORK, Jan. 18 (GenomeWeb News) - Sigma-Aldrich will acquire JRH Biosciences, a division of CSL Limited, for $370 million in cash, the company said today.

 

JRH, headquartered in Lenexa, Kan., supplies cell culture and sera products to the biopharmaceutical industry. It had approximately $150 million in sales in 2004, and was expecting a 10-percent growth in this figure in 2005, Sigma said.

 

JRH also has manufacturing facilities in the US, Europe, and Australia; and serum collection and processing centers in the US and Australia. It has approximately 400 employees worldwide.

 

Sigma said that it expects to fund the acquisition with a combination of existing cash, short-term debt, and three-year term debt.

 

Goldman Sachs acted as financial advisor on the transaction.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.